Durable Activity of Repotrectinib in Patients with ROS1 Fusion–Positive NSCLC Regardless of Previous Treatment with a ROS1 TKI
Findings from the TRIDENT-1 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1551 results
EMA Recommends Granting a Marketing Authorisation for Generic Eribulin
Mevlyq is a generic of Halaven, which has been authorised in the EU since 2011
Neoadjuvant Atezolizumab Plus Chemotherapy Is Safe and Has Promising Activity in Patients with Gastric and Gastro-oesophageal Junction Adenocarcinoma
Findings from the PANDA study
Potential Value of ctDNA NGS-based Analysis of Imatinib Resistant Secondary KIT Mutations to Select Second-Line Treatment for Patients with Advanced GIST
Findings from the exploratory analysis of the INTRIGUE study
Adding Pembrolizumab to Chemotherapy with or without Bevacizumab Improves Overall Survival Across Subgroups of Patients with Persistent, Recurrent, or Metastatic Cervical Cancer
Findings from subgroup analyses of the KEYNOTE-826 study
FDA Approves Enfortumab Vedotin-ejfv with Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer
Evidence for efficacy is based on the results from the EV-302/KN-A39 study
Mosunetuzumab Plus Polatuzumab Vedotin Shows Promise for Patients with Aggressive Relapsed or Refractory Aggressive Large B Cell Lymphoma
Findings from the primary analysis of an ongoing phase Ib/II study
Oligoprogression in Metastatic NSCLC Could Be Effectively Treated with SBRT Plus Standard-of-Care, Leading to Increase in PFS Compared with Standard-of-Care Only
Findings from the CURB study
Divarasib in Combination with Cetuximab Demonstrates a Manageable Safety Profile and Promising Activity in Patients with KRAS G12C-positive CRC
Findings from patients with colorectal cancer included in arm C of a phase Ib study
Osimertinib Shows Promising Activity in Previously Untreated Patients with Metastatic NSCLC Harbouring Uncommon EGFR Mutations Other than the Exon 20 Insertion
Findings from the UNICORN study
Mirvetuximab Soravtansine-gynx Shows a Significant Benefit Over Chemotherapy in Women with Platinum-Resistant, FRα-positive Ovarian Cancer
Findings from the MIRASOL study
FDA Approves Enzalutamide for Non-Metastatic Castration-Sensitive Prostate Cancer with Biochemical Recurrence
Evidence for efficacy is based on the results from the EMBARK study